# US 2023/0398204 A1 · Coronavirus Spike Glycoprotein With Improved Expression and Stability

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398204 A1
- Document ID: US20230398204A1
- Status: Published application
- Kind: A1
- Application number: 18/031,800
- Filed: 2020-10-21
- Published: 2023-12-14
- Earliest claimed: 2020-10-21
- Applicants: La Jolla Institute for Immunology
- Inventors: Erica Ollman Saphire; Eduardo Olmedillas; Colin Mann
- Web page: https://patentgrep.com/patent/US20230398204A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention includes a mutant coronavirus spike protein, methods of making and using, vaccines, vectors and nucleic acids, comprising at least one of the following modifications: a short flexible peptide linker or a rigid peptide linker in place of the furin cleavage site loop to genetically link an 51 and S2 subunit; at least one additional disulfide bond; or 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the resulting mutant coronavirus spike protein has at least one of: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein. In one example, the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof. Current SARS-CoV-2 variants include, e.g., B.1.1.7, B.1.1.7 with E484K, B.1.135, B.1.351, P.1, B.1.427, D614G, B.1.1351, or B.1.429, Lambda (i.e., C.37), Mu (i.e. B.1.621), and others.

## Claims

### Claim 1

A mutant coronavirus spike protein comprising at least one of the following modifications:
(1) a short flexible peptide linker or a rigid peptide linker in place of a furin cleavage site loop to genetically link an Si and S2 subunit;
(2) at least one additional disulfide bond; and
(3) 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus spike protein has at least one of: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein.

### Claim 2 (depends on 1)

The mutant coronavirus spike protein of claim 1, wherein the furin cleavage site loop is at position 676-690.

### Claim 3 (depends on 1)

The mutant coronavirus spike protein of claim 1, wherein the short flexible peptide linker is selected from at least one of: GGS (SEQ ID NO:34), GP (SEQ ID NO:35), GPGP (SEQ ID NO:36), GGSGGS (SEQ ID NO:37), or GGGSGGGS (SEQ ID NO:38).

### Claim 4 (depends on 1)

The mutant coronavirus spike protein of claim 1, wherein the 1, 2, 3, 4, or 5 proline mutations are selected from F817P, A892P, A899P, A942P, P986K, K986P, V987P, and P987V.

### Claim 5 (depends on 1)

The mutant coronavirus spike protein of claim 1, wherein the at least one additional disulfide bond is selected from F43C-G566C, G413C-P987C, Y707C-T883C, G1035C-V1040C, A701C-Q787C, G667C-L864C, V382C-R983C, and 1712C-I816C.

### Claim 6 (depends on 1)

The mutant coronavirus spike protein of claim 1, wherein the proline mutations are not K986P and V987P mutations.

### Claim 7 (depends on 1)

The mutant coronavirus spike protein of claim 1, wherein the at least one addition disulfide bond links the S2 to S2′ subunit, the S1 to S2 subunit, or the S1 to S2′ subunit.

### Claim 8 (depends on 1)

The mutant coronavirus spike protein of claim 1, wherein the higher stability is selected from: increased temperature stability, increased freeze/thaw stability, or increased lyophilization/resuspension stability.

### Claim 9 (depends on 1)

The mutant coronavirus spike protein of claim 1, further comprising a purification peptide at an amino-terminus, a carboxy-terminus, or both.

### Claim 10 (depends on 1)

The mutant coronavirus spike protein of claim 1, wherein the mutant coronavirus spike protein is selected from SEQ ID NOS:1 to 32.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The mutant coronavirus spike protein of any one of claims 1-10, wherein the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The mutant coronavirus spike protein of any one of claims 1-11, wherein the coronavirus is SARS-CoV-2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A nucleic acid encoding the mutant coronavirus spike protein of any one of claims 1-12.

### Claim 14 (depends on 13)

The nucleic acid of claim 13, further comprising a vector.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A cell comprising the mutant coronavirus spike protein of any one of claims 1-12 or the nucleic acid of claim 13.

### Claim 16 (depends on 15)

The cell of claim 15, wherein the cell is a human cell.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A vaccine composition comprising the mutant coronavirus spike protein of any one of claims 1-12 or nucleic acid of either claim 13 or claim 14, and a pharmaceutically acceptable excipient.

### Claim 18 (depends on 17)

The vaccine composition of claim 17, further comprising an adjuvant.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A nanoparticle comprising the mutant coronavirus spike protein of any one of claims 1-12.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 19)

The nanoparticle of claim 19, wherein the nanoparticle comprises at least two of the mutant coronavirus spike protein of any one of claims 1-12.

### Claim 21 (depends on 19)

The nanoparticle of claim 19, wherein the mutant coronavirus spike proteins are formed into dimers, trimers, or multimers.

### Claim 22 (depends on 19, 20, 21)

The nanoparticle of any one of claims 19-21, wherein the nanoparticles comprise ferritin nanoparticles, polymeric nanoparticles, or both.

### Claim 23

A method of making a mutant coronavirus spike protein comprising:
obtaining a nucleic acid sequence encoding a coronavirus spike protein; and
modifying the nucleic acid sequence of the coronavirus spike protein such that the amino acid sequence expressed by the nucleic acid sequence comprises at least one of:
linking the S1/S2 subunits of a coronavirus spike protein, by deleting a furin cleavage site loop and adding a short flexible peptide linker or a rigid peptide linker;
adding at least one additional disulfide bond; and
adding 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the expressed mutant coronavirus spike protein has at least one of: a higher stability or level of expression, than a non-modified coronavirus spike protein.

### Claim 24 (depends on 23)

The method of claim 23, further comprising the step of expressing the mutant coronavirus spike protein in a bacteria, fungi, mammalian cell, avian cell, insect cell, or plant cell.

### Claim 25 (depends on 23)

The method of claim 23, wherein the furin cleavage site loop is at position 676-690.

### Claim 26 (depends on 23)

The method of claim 23, wherein the linker is selected from at least one of: GGS (SEQ ID NO:34), GP (SEQ ID NO:35), GPGP (SEQ ID NO:36), GGSGGS (SEQ ID NO:37), or GGGSGGGS (SEQ ID NO:38).

### Claim 27 (depends on 23)

The method of claim 23, wherein the 1, 2, 3, 4, or 5 proline mutations are selected from F817P, A892P, A899P, A942P, P986K, K986P, V987P, and P987V.

### Claim 28 (depends on 23)

The method of claim 23, wherein the at least one additional disulfide bond is selected from F43C-G566C, G413C-P987C, Y707C-T883C, G1035C-V1040C, A701C-Q787C, G667C-L864C, V382C-R983C, or I712C-I816C.

### Claim 29 (depends on 23)

The method of claim 23, wherein the proline mutations are not K986P and V987P mutations.

### Claim 30 (depends on 23)

The method of claim 23, wherein the at least one addition disulfide bond links the S2 to S2′ subunit, the S1 to S2 subunit, or the S1 to S2′ subunit.

### Claim 31 (depends on 23)

The method of claim 23, wherein the higher stability is selected from: increased temperature stability, increased freeze/thaw stability, or increased lyophilization/resuspension stability.

### Claim 32 (depends on 23)

The method of claim 23, further comprising including a purification peptide at an amino-terminus, a carboxy-terminus, or both.

### Claim 33 (depends on 23)

The method of claim 23, wherein the mutant coronavirus spike protein expressed by the modified nucleic acid sequence is selected from SEQ ID NOS:1 to 32.

### Claim 34 (depends on 23)

The method of any one of claims 23, wherein the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof.

### Claim 35

A method of immunizing a subject in need thereof against a coronavirus, the method comprising:
identifying a subject in need of an immunization; and
administering to the subject to a mutant coronavirus spike protein comprising at least one of the following modifications:
a short flexible peptide linker or a rigid peptide linker in place of a furin cleavage site loop to genetically link an S1 and S2 subunit;
at least one additional disulfide bond; and
1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus spike protein has at least one of: a higher stability or a higher level of expression when compared to a non-modified coronavirus spike protein.

### Claim 36 (depends on 17, 18, 35)

The method of claim 35, wherein administering the mutant coronavirus spike protein comprises administering the vaccine composition of either of claim 17 or claim 18.

### Claim 37 (depends on 35)

The method of claim 35, wherein the mutant coronavirus spike protein has an amino acid sequence corresponding to any one of SEQ ID NOS:1 to 33.

### Claim 38 (depends on 35)

The method of claim 35, wherein the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof.

### Claim 39 (depends on 35)

The method of claim 35, further comprising isolating B cells from the immunized subject and obtaining a nucleic acid sequence of antibodies from the B cells, or fusing the isolated B cells with an immortalized cell to make a hybridoma.

### Claim 40

A nucleic acid sequence encoding a mutant coronavirus spike protein comprising:
one or more mutations that change an amino acid sequence of a coronavirus spike protein by at least one of:
linking the S1/S2 subunits of a coronavirus spike protein, by deleting a furin cleavage site loop and adding a short flexible peptide linker or a rigid peptide linker;
adding at least one additional disulfide bond; or
adding 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus spike protein has at least one of: higher stability or level of expression, than a non-modified coronavirus spike protein.

### Claim 41 (depends on 40)

The nucleic acid of claim 40, wherein the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof.

### Claim 42

A vector comprising a nucleic acid sequence encoding a mutant coronavirus spike protein comprising:
one or more mutations that change the encoded amino acid sequence by at least one of:
linking the S1/S2 subunits of a coronavirus spike protein, by deleting a furin cleavage site loop and adding a short flexible peptide linker or a rigid peptide linker;
adding at least one additional disulfide bond; and
adding 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus spike protein has at least one of: higher stability or level of expression, than a non-modified coronavirus spike protein.

### Claim 43 (depends on 42)

The vector of claim 42, where the vector is selected for expression in a bacteria, fungi, mammalian cell, avian cell, insect cell, or plant cell.

### Claim 44 (depends on 42)

The vector of claim 42, where the vector is in a bacteria, fungi, mammalian cell, avian cell, insect cell, or plant cell.

### Claim 45 (depends on 42)

The vector of claim 42, wherein the coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, or an emerging variant thereof.
